NMDA receptor pathways as drug targets

Since the mid 1980s, there has been a great deal of enthusiasm within both academia and industry about the therapeutic potential of drugs targeting the NMDA subtype of glutamate receptors. That early promise is just beginning to translate into approvable drugs. Here we review the reasons for this sl...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature neuroscience 2002-11, Vol.5 Suppl (11s), p.1039-1042
Hauptverfasser:	Kemp, John A, McKernan, Ruth M
Format:	Artikel
Sprache:	eng
Schlagworte:	Alzheimer's disease Animals Brain - drug effects Brain - metabolism Brain - physiopathology Brain Diseases - drug therapy Brain Diseases - metabolism Brain Diseases - physiopathology Brain research Clinical trials Drug Design Drug dosages Drug Industry - trends Excitatory Amino Acid Agonists - therapeutic use Excitatory Amino Acid Antagonists - pharmacology Excitatory Amino Acid Antagonists - therapeutic use Humans Ion channels Ischemia Ligands Neural Pathways - drug effects Neural Pathways - metabolism Neural Pathways - physiopathology Neurons Neurosciences Neurosciences - trends Neurotransmitter receptors Physiological aspects Receptors, N-Methyl-D-Aspartate - drug effects Receptors, N-Methyl-D-Aspartate - metabolism Stroke
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Since the mid 1980s, there has been a great deal of enthusiasm within both academia and industry about the therapeutic potential of drugs targeting the NMDA subtype of glutamate receptors. That early promise is just beginning to translate into approvable drugs. Here we review the reasons for this slow progress and critically assess the future prospects for drugs that act on NMDA receptor pathways, including potential treatments for some major disorders such as stroke and Alzheimer's disease, for which effective therapies are still lacking.
ISSN:	1097-6256 1546-1726
DOI:	10.1038/nn936